[go: up one dir, main page]

BRPI0513402A - miméticos de apolipoproteìna a1 e usos dos mesmos - Google Patents

miméticos de apolipoproteìna a1 e usos dos mesmos

Info

Publication number
BRPI0513402A
BRPI0513402A BRPI0513402-1A BRPI0513402A BRPI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A BR PI0513402 A BRPI0513402 A BR PI0513402A
Authority
BR
Brazil
Prior art keywords
apolipoprotein
mimetics
cholesterol levels
plasma cholesterol
provides
Prior art date
Application number
BRPI0513402-1A
Other languages
English (en)
Inventor
William W Bachovchin
Eugenio A Cefali
Original Assignee
Tufts College
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College, Kos Life Sciences Inc filed Critical Tufts College
Publication of BRPI0513402A publication Critical patent/BRPI0513402A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MIMéTICOS DE APOLIPOPROTEìNA A1 E USOS DOS MESMOS A presente invenção fornece peptidomiméticos obtidos a partir de Apolipoproteína A-I, a qual é útil para influenciar beneficamente parâmetros lipídicos e/ou níveis de colesterol de plasma. A invenção também fornece composições farmacêuticas e métodos de tratamento para níveis elevados de colesterol de plasma.
BRPI0513402-1A 2004-07-16 2005-07-15 miméticos de apolipoproteìna a1 e usos dos mesmos BRPI0513402A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0513402A true BRPI0513402A (pt) 2008-05-06

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513402-1A BRPI0513402A (pt) 2004-07-16 2005-07-15 miméticos de apolipoproteìna a1 e usos dos mesmos

Country Status (12)

Country Link
US (3) US7569546B2 (pt)
EP (1) EP1771473B1 (pt)
JP (1) JP5048486B2 (pt)
KR (1) KR101185609B1 (pt)
CN (1) CN101076541A (pt)
AU (1) AU2005275009B2 (pt)
BR (1) BRPI0513402A (pt)
CA (1) CA2574007A1 (pt)
IL (1) IL180733A (pt)
NO (1) NO20070876L (pt)
TW (1) TWI377066B (pt)
WO (1) WO2006020040A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2574007A1 (en) * 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof
AU2005287004B2 (en) * 2004-09-16 2011-03-17 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
NZ555826A (en) 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
CA2653840A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
CA2659655A1 (en) * 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
DK2121746T3 (da) * 2006-12-13 2012-03-05 Univ California Potente og selektive mediatorer af kolesterolefflux
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
CA2708719A1 (en) * 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
PT2396017E (pt) * 2009-02-16 2015-10-22 Cerenis Therapeutics Holding Sa Miméticos da apolipoproteína a-i
AU2011268419A1 (en) * 2010-06-15 2013-01-31 Carl Lawyer Compositions and methods for the treatment of atherosclerosis
SMT201900194T1 (it) * 2011-02-07 2019-05-10 Cerenis Therapeutics Holding Sa Complessi lipoproteici e loro produzione e usi
EP2983687B1 (en) 2013-03-15 2019-09-04 The Regents of The University of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
WO2018136803A1 (en) * 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
JP7521877B2 (ja) 2018-09-28 2024-07-24 マクセル株式会社 光照射装置
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
AU2021354095A1 (en) 2020-10-01 2023-06-08 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
AU2022258815A1 (en) 2021-04-15 2023-10-19 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN119384269A (zh) 2022-04-06 2025-01-28 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗眼病的方法
AU2023251245A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
AU2023285382A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319498B1 (en) * 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
CA2574007A1 (en) * 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof
AU2005287004B2 (en) * 2004-09-16 2011-03-17 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
NZ555826A (en) * 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles

Also Published As

Publication number Publication date
EP1771473B1 (en) 2012-12-26
CA2574007A1 (en) 2006-02-23
US8124580B2 (en) 2012-02-28
EP1771473A2 (en) 2007-04-11
KR20070095862A (ko) 2007-10-01
US20120259091A1 (en) 2012-10-11
IL180733A (en) 2013-01-31
WO2006020040A3 (en) 2006-07-06
JP5048486B2 (ja) 2012-10-17
NO20070876L (no) 2007-03-30
AU2005275009A1 (en) 2006-02-23
KR101185609B1 (ko) 2012-09-24
US20100009919A1 (en) 2010-01-14
WO2006020040A2 (en) 2006-02-23
JP2008506709A (ja) 2008-03-06
AU2005275009B2 (en) 2011-12-08
IL180733A0 (en) 2007-06-03
CN101076541A (zh) 2007-11-21
US20060069030A1 (en) 2006-03-30
TW200612977A (en) 2006-05-01
US7569546B2 (en) 2009-08-04
TWI377066B (en) 2012-11-21

Similar Documents

Publication Publication Date Title
BRPI0513402A (pt) miméticos de apolipoproteìna a1 e usos dos mesmos
WO2006045010A3 (en) Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP2452683A3 (en) Methods for treating atherosclerosis
EP2522721A3 (en) Modified lecithin-cholesterol acyltransferase enzymes
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
TW200736253A (en) Pyridopyrazine derivatives and their use
EP2402443A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
HN2009001112A (es) Inhibidores de la actividad de la akt
BRPI0607555A2 (pt) inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2008011611A3 (en) Compounds and compositions as itpkb inhibitors
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions
WO2007116243A3 (en) Method for treating fibromyalgia and related conditions
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2012057492A3 (ko) 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
BRPI0513283A (pt) combinações de estatina com broncodilatadores
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
DE602005010270D1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
WO2008034071A3 (en) Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2006047312A3 (en) COMPOSITIONS AND METHODS FOR MODULATING PGC-1β TO TREAT LIPID-RELATED DISEASES AND DISORDERS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.